Your selection
Innovation / 02.10.2024
Eckert & Ziegler: Spin-off of Pentixapharm AG Registered with the Commercial Register
Berlin, 2 October 2024.
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) announces that the spin-off resolution approved at the Annual General Meeting on 26 June 2024 was entered in the commercial register of the Charlottenburg (Berlin) District Court today. With the entry in the commercial register of Eckert & Ziegler SE, the spin-off of Pentixapharm AG became legally effective. All shares in Pentixapharm AG held by Eckert & Ziegler have thus been legally transferred from Eckert & Ziegler SE to Pentixapharm Holding AG.
In compensation, the shareholders of Eckert & Ziegler SE will receive Pentixapharm Holding AG shares at a ratio of 1:1. The number of Eckert & Ziegler shares held by each Eckert & Ziegler shareholder after the close of trading today, taking into account any outstanding stock market transactions, will determine their entitlement. All Pentixapharm Holding AG shares created as part of the spin-off are expected to be admitted to the Regulated Market of the Frankfurt Stock Exchange in the Prime Standard segment on 2 October 2024.
Initial trading of the Pentixapharm Holding AG shares is scheduled for 3 October 2024. On the same day, the listing of the Eckert & Ziegler SE shares ‘ex spin-off’ is planned. The deposit-side posting of the Pentixapharm Holding shares to the securities accounts of Eckert & Ziegler shareholders is expected to take place on 7 October 2024.
Further information on the IPO of Pentixapharm AG can be found here: www.pentixapharm.com
About Eckert & Ziegler.
Eckert & Ziegler SE with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.
Overview News
News Buch Berlin
Eckert & Ziegler: Illuccix® PSMA-PET Imaging Agent Receives Approval in Germany
Eckert & Ziegler (ISIN DE0005659700, SDAX) congratulates Telix Pharmaceuticals Limited (Telix) on the approval of its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-6...
more ...Joint Berlin Data & AI Center planned
Data-driven research is crucial for tackling societal challenges. In a collaboration that is so far unique, Berlin's Universities of Excellence, the Max Delbrück Center, and the Helmholtz-Zentrum Berl...
more ...Eckert & Ziegler Organizes Third Boston Radionuclide Theranostics Forum
Eckert & Ziegler successfully completes the 3rd annual Boston Radionuclide Theranostics Forum, underscoring its continued leadership in the radiopharmaceutical industry.
more ...Events Buch Berlin
21.06.2025, 14:00
Offener Garten und Fète de la Musique im ÖkoGut Buch
Interessierte sind herzlich in den Garten eingeladen
more ...21.06.2025, 19:30
Open Air Sommerkino Hobrechtsfelde 2025
Zum Saisonstart gibt es den DEFA-Klassiker „Heißer Sommer“
more ...28.06.2025, 16:00
Lange Nacht der Wissenschaften 2025
Mitmach-Experimente, Shows, Laborführungen
more ...